Tawee Tanvetyanon, MD

BOARD CERTIFICATION:
          •  Medical Oncology
          •  Hematology

FELLOWSHIP:
          •  Loyola University Chicago, Stritch School of Medicine, Illinois - Medical Oncology & Hematology

RESIDENCY:
          •  Albert Einstein Medical Center at Thomas Jefferson Medical College, Pennsylvania

MEDICAL SCHOOL:
          •  Chulalongkorn University in Bangkok, Thailand - MD

• Tanvetyanon T, Finley DJ, Fabian T, Riquet M, Voltolini L, Kocaturk C, Fulp WJ, Cerfolio RJ, Park BJ, Robinson LA. Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. Ann Oncol. 2013 Apr;24(4):889-894. Pubmedid: 23136230.


• Kumar V, Nath K, Berman CG, Kim J, Tanvetyanon T, Chiappori AA, Gatenby RA, Gillies RJ, Eikman EA. Variance of SUVs for FDG-PET/CT is Greater in Clinical Practice Than Under Ideal Study Settings. Clin Nucl Med. 2013 Mar;38(3):175-182. Pubmedid: 23354032.


• May JT, Rao N, Sabater RD, Boutrid H, Caudell JJ, Merchant F, Han G, Padhya TA, McCaffrey JC, Tanvetyanon T, Deconti R, Kish J, McCaffrey TV, Trotti A. Intensity-modulated radiation therapy as primary treatment for oropharyngeal squamous cell carcinoma. Head Neck. 2013 Mar. Pubmedid: 23468387.


• Phillips KM, Jim HS, Small BJ, Tanvetyanon T, Roberts WS, Jacobsen PB. Effects of Self-directed Stress Management Training and Home-based Exercise on Stress Management Skills in Cancer Patients Receiving Chemotherapy. Stress Health. 2012 Dec;28(5):368-375. Pubmedid: 22972771.


• Fury MG, Sherman E, Lisa D, Agarwal N, Algazy K, Brockstein B, Langer C, Lim D, Mehra R, Rajan SK, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marrone S, Ng K, Xiao H, Haque S, Pfister DG. A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer. J Natl Compr Canc Netw. 2012 Nov;10(11):1391-1398. Pubmedid: 23138167.


• Salah S, Tanvetyanon T, Abbasi S. Metastatectomy for extra-cranial extra-adrenal non-small cell lung cancer solitary metastases: Systematic review and analysis of reported cases. Lung Cancer. 2012 Jan;75(1):9-14. Pubmedid: 21864934.


• Tanvetyanon T, Corman M, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Bepler G, Siegel E, Shibata D, Malafa M, Jacobsen PB. Quality of Care in Non-Small-Cell Lung Cancer: Findings From 11 Oncology Practices in Florida. J Oncol Pract. 2011 Nov;7(6):e25-e31. Pubmedid: 22379428.


• Faul LA, Jim HS, Minton S, Fishman M, Tanvetyanon T, Jacobsen PB. Relationship of exercise to quality of life in cancer patients beginning chemotherapy. J Pain Symptom Manage. 2011 May;41(5):859-869. Pubmedid: 21330097.


• Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C. Phase II Trial of Induction Gemcitabine and Carboplatin Followed by Conformal Thoracic Radiation to 74 Gy with Weekly Paclitaxel and Carboplatin in Unresectable Stage III Non-small Cell Lung Cancer. J Thorac Oncol. 2011 Mar;6(3):553-558. Pubmedid: 21289520.


• Tanvetyanon T, Robinson L, Sommers KE, Haura E, Kim J, Altiok S, Bepler G. Relationship between Tumor Size and Survival among Patients with Resection of Multiple Synchronous Lung Cancers. J Thorac Oncol. 2010 Jul;5(7):1018-1024. Pubmedid: 20453687.


• Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L, Neuger A, Song L, Rawal B, Schell MJ, Bepler G. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 2010 Mar;28(8):1387-1394. Pubmedid: 20142592. Pmcid: PMC3040065.


• Tanvetyanon T. Quality-of-care indicators for non-small cell lung cancer. Cancer Control. 2009 Oct;16(4):335-341. Pubmedid: 19910920.


• Tanvetyanon T, Qin D, Padhya T, McCaffrey J, Zhu W, Boulware D, DeConti R, Trotti A. Outcomes of postoperative concurrent chemoradiotherapy for locally advanced major salivary gland carcinoma. Arch Otolaryngol Head Neck Surg. 2009 Jul;135(7):687-692. Pubmedid: 19620591.


• Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, Deconti R, Trotti A. Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer. J Clin Oncol. 2009 Apr;27(12):1983-1991. Pubmedid: 19289616.


• Tanvetyanon T, Murtagh R, Bepler G. Rupture of a cerebral arteriovenous malformation in a patient treated with bevacizumab. J Thorac Oncol. 2009 Feb;4(2):268-269. Pubmedid: 19179909.


• Tanvetyanon T, Qin D, Padhya T, Kapoor R, McCaffrey J, Trotti A. Survival outcomes of squamous cell carcinoma arising from sinonasal inverted papilloma: report of 6 cases with systematic review and pooled analysis. Am J Otolaryngol. 2009 Jan;30(1):38-43. Pubmedid: 19027511.


• Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA. Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol. 2008 Oct;3(10):1112-1118. Pubmedid: 18827606. Pmcid: PMC2639211.


• Tanvetyanon T, Eikman EA, Sommers E, Robinson L, Boulware D, Bepler G. Computed tomography response, but not positron emission tomography scan response, predicts survival after neoadjuvant chemotherapy for resectable non-small-cell lung cancer. J Clin Oncol. 2008 Oct;26(28):4610-4616. Pubmedid: 18824709.


• Tanvetyanon T, Bepler G. Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. Cancer. 2008 Jul;113(1):150-157. Pubmedid: 18429004.


• Tanvetyanon T, Robinson L, Schell M, Strong V, Kapoor R, Coit D, BeplerG. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrena metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol. 2008 Mar;26(7):1142-1147. Pubmedid: 18309950.


• Tanvetyanon T, Soares H, Djulbegovic B, Jacobsen P, Bepler G. A systematic review of quality of life associated with standard chemotherapy regimens for advanced non-small cell lung cancer. J Thorac Oncol. 2007 Dec;2(12):1091-1097. Pubmedid: 18090580.


• Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol. 2007 Jul;25(19):2741-2746. Pubmedid: 17602079.


• Tanvetyanon T. Understanding the uncommon thoracic tumors. Cancer Control. 2006 Oct;13(4):252-253. Pubmedid: 17075561.


• Tanvetyanon T, Stiff P. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006 Jun;17(6):897-907. Pubmedid: 16547070.


• Tanvetyanon T, Choudhury A. Severity, risk factors, and physician practices in the management of anemia during concurrent chemoradiation for head and neck carcinoma. Cancer. 2006 Apr;106(7):1554-1559. Pubmedid: 16518817.


• Tanvetyanon T, Garrity ER, Albain KS. Acute lung injury associated with vinorelbine. J Clin Oncol. 2006 Apr;24(12):1952-1953. Pubmedid: 16622272.


• Tanvetyanon T, Choudhury AM. Physician practice in the discontinuation of statins among patients with advanced lung cancer. J Palliat Care. 2006;22(4):281-285. Pubmedid: 17263055.


• Tanvetyanon T. Treatment of localized lymphoma. N Engl J Med. 2005 Jun;352(23):2449-2451. Pubmedid: 15944432.


• Tanvetyanon T. Medical costs associated with chiropractic care. Arch Intern Med. 2005 Jun;165(11):1313-1314. Pubmedid: 15956016.


• Tanvetyanon T. Molecular prediction of recurrence of breast cancer. N Engl J Med. 2005 Apr;352(15):1605-1607. Pubmedid: 15832454.


• Tanvetyanon T, Hines E J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. Cancer. 2005 Apr;103(8):1756-1757. Pubmedid: 15751014.


• Tanvetyanon T, Clark J, Campbell S, Lo S. Neoadjuvant therapy: an emerging concept in oncology. South Med J. 2005 Mar;98(3):338-344. Pubmedid: 15813161.


• Tanvetyanon T, Elmishad AG, Carbone M. Development of malignant mesothelioma during treatment for prolymphocytic leukemia: is asbestos or simian virus 40 a link?. Anticancer Res. 2005 Jan;25(1B):429-433. Pubmedid: 15816607.


• Tanvetyanon T. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2005 Jan;97(1):70. Pubmedid: 15632382.


• Tanvetyanon T. Talking about death with dying children. N Engl J Med. 2005 Jan;352(1):91-92. Pubmedid: 15635780.


• Tanvetyanon T, Stiff P. Recurrent steroid-responsive pancreatitis associated with myelodysplastic syndrome and transformations. Leuk Lymphoma. 2005 Jan;46(1):151-154. Pubmedid: 15621795.


• Tanvetyanon T. Physician practices of bone density testing and drug prescribing to prevent or treat osteoporosis during androgen deprivation therapy. Cancer. 2005 Jan;103(2):237-241. Pubmedid: 15597384.


• Tanvetyanon T. Telephone psychotherapy and care management for depression. Jama. 2004 Dec;292(22):2720le-2720le. Pubmedid: 15585725.


• Tanvetyanon T. Treatment of von Willebrand's Disease. N Engl J Med. 2004 Nov;351(22):2345-2346. Pubmedid: 15570685.


• Tanvetyanon T, Nand S. Pancytopenia in hereditary haemorrhagic telangiectasia. Br J Haematol. 2004 Nov;127(4):371-371. Pubmedid: 15521911.


• Tanvetyanon T. Re: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol. 2004 Nov;172(5 Pt 1):2082-2082. Pubmedid: 15540794.


• Tanvetyanon T. Which patient with a do-not-intubate order is a candidate for noninvasive ventilation. Crit Care Med. 2004 Oct;32(10):2148-2150. Pubmedid: 15483429.


• Tanvetyanon T, Stiff P. Second allogeneic transplantation using a reduced-intensity preparative regimen for relapsed myelofibrosis. Am J Hematol. 2004 Oct;77(2):204-205. Pubmedid: 15389913.


• Tanvetyanon T. Arterial thrombosis in systemic lupus erythematosus. N Engl J Med. 2004 Oct;351(18):1910-1911. Pubmedid: 15515221.


• Tanvetyanon T, Toor A, Stiff P. Post-transplant air-leak syndrome. Br J Haematol. 2004 Sep;126(6):758-758. Pubmedid: 15352978.


• Nand S, Tanvetyanon T. Proton pump inhibitors and iron deficiency: is the connection real. South Med J. 2004 Sep;97(9):799-799. Pubmedid: 15455957.


• Tanvetyanon T, Ratanatharathorn V, Leopairat J. Mucoepidermoid carcinoma of the lung presenting as a cavitary lesion. J Med Assoc Thai. 2004 Aug;87(8):988-991. Pubmedid: 15471307.


• Tanvetyanon T. Adjuvant treatment of breast cancer with exemestane. N Engl J Med. 2004 Jul;351(1):100-102. Pubmedid: 15237463.


• Tanvetyanon T. HER-2 and fluorescent in situ hybridization to evaluate breast cancer. JAMA. 2004 Jul;292(3):328. Pubmedid: 15265845.


• Tanvetyanon T, Choudhury A. Fatal acute tumor lysis syndrome, hepatic encephalopathy and flare phenomenon following combined androgen blockade. J Urol. 2004 Apr;171(4):1627-1627. Pubmedid: 15017238.


• Tanvetyanon T, Nand S. Herpes zoster during treatment with arsenic trioxide. Ann Hematol. 2004 Mar;83(3):198-200. Pubmedid: 15064871.


• Tanvetyanon T, Choudhury A. Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa. Ann Pharmacother. 2004 Mar;38(3):418-421. Pubmedid: 14970365.


• Tanvetyanon T. Screening for primary human immunodeficiency virus infection. Arch Intern Med. 2004 Mar;164(6):680-680. Pubmedid: 15037504.


• Tanvetyanon T. Is hypocalcemia during therapy with zoledronic acid or other bisphosphonatesbeneficial to cancer patients. Med Hypotheses. 2004;63(4):764-765. Pubmedid: 15325030.


• Tanvetyanon T, Nand S. Overcoming recurrent cutaneous reactions from imatinib using once-weekly dosing. Ann Pharmacother. 2003 Dec;37(12):1818-1820. Pubmedid: 14632593.


• Tanvetyanon T, Tapaneeyakorn J. Octreotide for bleeding as a result of hepatocellular carcinoma invasion of the gastrointestinal tract. J Gastroenterol Hepatol. 2003 Feb;18(2):231-232. Pubmedid: 12542614.


• Tanvetyanon T, Stadtmauer EA, Kerson LA. Concurrent administration of interferon alfa-2b and beta-1a. Ann Pharmacother. 2003 Jan;37(1):77-79. Pubmedid: 12503938.


• Tanvetyanon T, Leighton J. Life-sustaining treatments in patients who died of chronic congestive heart failure compared with metastatic cancer. Crit Care Med. 2003 Jan;31(1):60-64. Pubmedid: 12544994.


• Sirisinha T, Ratanatharathorn V, Jirajarus M, Sirilerttrakul S, Silpakit C, Sirachainan E, Tanvetyanon T. The European Organization for Research and Treatment of Cancer quality of life questionnaire: translation and reliability study of the Thai version. J Med Assoc Thai. 2002 Nov;85(11):1210-1219. Pubmedid: 12546319.


• Tanvetyanon T, Walkenstein M, Marra A. Inaccurate glucose determination by fingerstick in a patient with peripheral arterial disease. Ann Intern Med. 2002 Nov;137(9):W1-W1. Pubmedid: 12416976.


• Tanvetyanon T, Leighton J. Severe anemia and marrow plasmacytosis as presentation of Sjogren's syndrome. Am J Hematol. 2002 Mar;69(3):233-233. Pubmedid: 11891816.


• Tanvetyanon T, Dissin J, Selcer U. Hyperthermia and chronic pancerebellar syndrome after cocaine abuse. Arch Intern Med. 2001 Feb;161(4):608-610. Pubmedid: 11252123.


• Tanvetyanon T, Cohn J. Eligibility for outpatient treatment with low-molecular-weight heparin in venous thromboembolism. Arch Intern Med. 2000 Mar;160(6):869-870. Pubmedid: 10737288.


• Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, Gilbert J, Mehra R, Moore DT, Sheikh A, Hoskins J, Hayward MC, Zhao N, O'Connor W, Weck KE, Cohen RB, Cohen EE. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012 Apr;18(7):2056-2065. Pubmedid: 22241789.


• Tanvetyanon T. Reply to the article "The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer" by K.P. Weinfurt et al. (Ann Oncol 2005; 16: 579-584). Ann Oncol. 2005 Oct;16(10):1712-1713. Pubmedid: 15972282.

Dr. Tanvetyanon's effort is directed toward pallate cancer and treatment-related distress. Additional attention is given to those patients with multiple co-morbidities, impaired physical function, advanced age, or advanced disease. Dr. Tanvetyanon specializes in both Thoracic malignancies (lung cancer, mesothelioma, thymoma) and cancers of the head and neck.